Targeting EGFR using traditional targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors (TKIs), as radiosensitizers have gained moderate success in non-small-cell lung cancer (NSCLC), but failed in GBM and HNSCC to improve OS rates (108, 109). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.